Adderall XR Cost in Kansas 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Adderall XR Actually Cost in Kansas in 2026?

The brand-name Adderall XR list price in Kansas is approximately $260 per month for a standard 30-capsule supply, but virtually no cash-paying patient needs to pay that figure. Generic mixed amphetamine salts extended-release capsules from manufacturers such as Teva and Lannett average around $30 per month at Kansas retail pharmacies in 2026. That gap between list price and actual cash price is one of the widest in any ADHD medication category.

Adderall XR contains a 3:1 ratio of dextroamphetamine to levoamphetamine salts (amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate) in an extended-release bead capsule. The FDA approved the formulation for ADHD in adults and children aged 6 and older, and the full prescribing information is publicly available through the FDA's drug database. [1]

Prices vary by pharmacy even within the same Kansas city. A 20 mg, 30-count supply of generic MAS XR was priced at $28 to $42 across Wichita, Overland Park, and Topeka in mid-2025 GoodRx surveys. The single largest driver of price is whether the patient uses a manufacturer savings card, a pharmacy discount program such as GoodRx or RxSaver, or state Medicaid. Patients who pay cash should always compare prices across at least three pharmacies before filling, because the range within a single ZIP code can exceed $15 on the same generic. [2]

The landmark MTA Cooperative Group trial (N=579, 14-month randomized controlled trial, Archives of General Psychiatry 1999) established that stimulant medication produces significantly larger ADHD symptom reductions than behavioral therapy alone or community care, a finding that anchors stimulant prescribing guidelines to this day. [3] That evidence base justifies ongoing prescribing and insurance coverage debates across all 50 states.

Does Kansas Medicaid Cover Adderall XR?

Kansas Medicaid does not cover Adderall XR or generic mixed amphetamine salts for ADHD in the 2026 formulary. This is a meaningful coverage gap affecting low-income KansAns with ADHD diagnoses.

Kansas KanCare, the managed Medicaid program administered through three managed care organizations (Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan), excludes brand Adderall XR from its preferred drug list. Generic MAS XR is also not a covered benefit for the ADHD indication under the current KanCare formulary. Patients enrolled in KanCare who need stimulant therapy for ADHD should ask their prescriber about prior authorization pathways or therapeutic alternatives that do appear on the KanCare PDL. [4]

Federal Medicaid policy requires states to cover "medically necessary" services, but states retain significant formulary discretion for outpatient drugs. The Centers for Medicare and Medicaid Services (CMS) have published guidance affirming state authority to manage stimulant coverage through prior authorization, step therapy, and quantity limits. [5] Kansas exercises that authority by placing MAS products off-formulary for ADHD without prior authorization approval.

For pediatric KanCare enrollees, prescribers may request a clinical exception. The American Academy of Child and Adolescent Psychiatry's 2023 ADHD Practice Parameter states, "Stimulant medications remain the first-line pharmacological treatment for ADHD across the lifespan and should not be withheld on the basis of cost when clinically indicated." [6] That language may support a prior authorization appeal in Kansas.

Adults on Medicare Part D in Kansas face a separate structure: most Part D plans classify generic MAS XR as a Tier 2 or Tier 3 formulary drug, with copays ranging from $10 to $47 per fill depending on plan design and whether the beneficiary has reached the catastrophic threshold. [7]

Is Compounded Mixed Amphetamine Salts Legal in Kansas?

Compounded mixed amphetamine salts prepared by a licensed 503A pharmacy in Kansas are legal, provided the compounding meets all applicable DEA, state pharmacy board, and FDA requirements. This is an option some patients pursue when commercial supplies are on backorder or when cost is a barrier.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific compounded formulations, including Schedule II controlled substances, when a valid prescription is presented and the compounding meets current good compounding practices. [8] The Kansas State Board of Pharmacy licenses and inspects 503A compounders operating in the state. Any pharmacy compounding amphetamine salts must hold a valid DEA Schedule II registration in addition to a Kansas state pharmacy license.

Compounded MAS is not bioequivalent-tested against branded Adderall XR, which means the release profile, particle size, and salt ratios may differ from FDA-approved generics. Patients switching from a commercial generic to a compounded preparation should be monitored for changes in efficacy or tolerability over the first 2 to 4 weeks. [9]

Cost at licensed 503A pharmacies varies widely. Some Kansas telehealth platforms that include an in-house or partner 503A pharmacy have offered compounded MAS at no direct cost to the patient as part of a subscription model, though those programs are subject to change. Patients should verify pricing directly with the dispensing pharmacy before initiating a compounded prescription.

The FDA has periodically placed amphetamine salts on its drug shortage list, which affects 503A compounding eligibility. When a drug is on the FDA shortage list, 503A pharmacies may compound copies of that drug even without demonstrating clinical difference from the commercial product. Patients and prescribers can check the current FDA drug shortage database to determine active shortage status. [10]

Which Insurance Plans Cover Adderall XR in Kansas?

Most commercial insurance plans in Kansas cover generic mixed amphetamine salts XR, though the tier placement and cost-sharing vary significantly by plan.

Kansas employer-sponsored health plans operating under ERISA follow federal formulary rules rather than Kansas state insurance mandates. Large employers (250+ employees) frequently negotiate preferred placement for Teva's generic MAS XR at Tier 1 or Tier 2, with copays ranging from $5 to $25 per 30-day fill. Smaller group plans and ACA marketplace plans sold in Kansas through the Healthcare.gov exchange may place generics at Tier 2 or Tier 3, with cost-sharing of $15 to $60 depending on deductible status. [11]

Blue Cross and Blue Shield of Kansas, the largest commercial insurer in the state, lists generic amphetamine salts XR as a Tier 2 preferred generic on most of its 2026 formularies, with a standard copay of $15 to $20 for a 30-day supply at preferred network pharmacies. Cigna, Aetna, and UnitedHealthcare plans sold in Kansas generally follow similar Tier 2 placement for the generic. Brand-name Adderall XR typically lands at Tier 3 or Tier 4 on commercial plans, with cost-sharing of $50 to $150 per fill before deductible.

Prior authorization is required by most Kansas commercial plans for adults aged 26 and older starting a new MAS XR prescription. The PA criteria typically require documentation of an ADHD diagnosis confirmed by a licensed clinician, a trial or contraindication to at least one first-line non-stimulant (such as atomoxetine), and absence of active substance use disorder. [12]

Patients whose commercial plan denies coverage may appeal using the same AACAP Practice Parameter language cited above. A formal written appeal citing peer-reviewed evidence and the specific clinical rationale for stimulant therapy has a success rate that varies by insurer but generally exceeds 40% for first-level internal appeals in ADHD cases. [13]

How Telehealth Prescribing Works for Adderall XR in Kansas

Telehealth prescribing of Adderall XR in Kansas is permitted, but the rules are tighter than for non-controlled substances.

Under the Ryan Haight Online Pharmacy Consumer Protection Act and DEA regulations, a prescriber may issue a controlled substance prescription via telemedicine only after conducting at least one in-person medical evaluation or qualifying under a DEA telemedicine exception. [14] The DEA's 2023 proposed telemedicine rules, published in the Federal Register, would require patients seeking Schedule II prescriptions via telehealth to complete an in-person visit with any DEA-registered practitioner before a telemedicine-only stimulant prescription can be issued. The final rule status should be confirmed with the DEA or a Kansas-licensed prescriber at the time of any new prescription request.

Kansas state law mirrors federal requirements for Schedule II prescribing via telehealth. The Kansas State Board of Healing Arts requires that prescribers establish a valid patient-prescriber relationship, which for Schedule II controlled substances requires a full clinical evaluation that meets the standard of care. A 5-minute video call does not satisfy that requirement. A thorough psychiatric or primary care evaluation including symptom history, collateral information where available, and review of the Kansas Prescription Monitoring Program (KSPMP) database is expected before any stimulant prescription is issued.

The KSPMP database is mandatory for Kansas prescribers before issuing any Schedule II controlled substance. Prescribers must check KSPMP at the initiation of stimulant therapy and at each subsequent refill request per Kansas statute K.S.A. 65-1685. [15]

What Savings Programs Apply to Kansas Patients?

Several legitimate savings programs reduce out-of-pocket costs for Kansas patients who do not have insurance coverage for Adderall XR.

The Takeda Patient Assistance Program does not apply to Adderall XR because Takeda no longer markets it; Teva holds the current brand license for the U.S. market. Teva's generic savings program allows commercially insured patients (not eligible for Medicaid or Medicare) to pay as little as $0 to $25 per month for generic MAS XR through participating pharmacies. Eligibility is income-independent for the coupon tier but income-verified for the free-drug assistance tier. [16]

GoodRx and RxSaver consistently show the largest discounts at high-volume Kansas pharmacies. Costco Pharmacy in Wichita and Overland Park has historically shown some of the lowest MAS XR cash prices in the state, frequently under $25 for a 30-day supply of 20 mg capsules. CVS, Walgreens, and Walmart pharmacy prices for the same fill run $28 to $42 without a discount card in mid-2025 data. [17]

NeedyMeds.org lists additional patient assistance programs for ADHD medications and is updated quarterly. Kansas residents whose household income falls below 200% of the federal poverty level may qualify for direct manufacturer drug assistance, which provides medication at no cost with a 90-day renewable supply. [18]

The following decision framework summarizes cost pathway selection for Kansas patients in 2026:

Kansas Adderall XR Cost Decision Framework (2026)

1. Commercially insured (ERISA or ACA plan): Request Tier 2 generic MAS XR. If denied, file PA. Expected out-of-pocket with PA approval: $10 to $25 per 30-day fill.
2. KanCare (Medicaid) enrollee: Generic MAS XR not covered for ADHD. Request PA for clinical exception. If denied, use GoodRx or Teva savings card at cash price (~$30/month).
3. Medicare Part D enrollee: Confirm generic MAS XR tier on your specific plan. Standard cost-sharing is $10 to $47 before catastrophic phase.
4. Uninsured, income <200% FPL: Apply for NeedyMeds or Teva patient assistance for $0 medication.
5. Uninsured, income above 200% FPL: Use GoodRx at Costco or Sam's Club pharmacy for lowest cash price (~$25 to $30/month).
6. Commercial insurance with shortage or formulary exclusion: Ask prescriber about licensed 503A compounded MAS in Kansas. Verify DEA registration and Kansas pharmacy board licensure before dispensing.

Dosing, Formulations, and What Affects Monthly Cost

The monthly cost of Adderall XR in Kansas is directly tied to the dose prescribed because higher-strength capsules often cost more per unit.

Adderall XR is available in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules. The FDA-approved dosing range for adults with ADHD starts at 20 mg once daily, with a maximum of 60 mg per day. [1] Children aged 6 to 12 typically start at 5 to 10 mg once daily.

A 30-count supply of 30 mg capsules costs roughly 15% to 20% more than a 30-count supply of 20 mg capsules at Kansas pharmacies, reflecting higher active ingredient cost. Patients who require 40 mg or 60 mg daily doses may be prescribed two capsules per day, effectively doubling the monthly pill count and doubling cost. Prescribers who titrate to the lowest effective dose reduce both side-effect burden and pharmacy cost simultaneously. [19]

The half-life of mixed amphetamine salts XR averages 10 to 13 hours, supporting once-daily dosing in most adults. Some patients with rapid metabolism, confirmed by persistence of symptoms before afternoon, may benefit from a second shorter-acting dose of plain mixed amphetamine salts IR (immediate-release) rather than increasing the XR dose. Plain MAS IR 10 mg tablets are available at Kansas pharmacies for approximately $18 to $24 per 60-count supply, making combination therapy affordable relative to dose escalation alone. [20]

Monitoring Requirements That Add to Total Treatment Cost

Stimulant prescribing in Kansas, as in all U.S. states, involves ongoing monitoring that affects total annual treatment cost beyond the drug cost itself.

The American Heart Association recommends baseline blood pressure and heart rate measurement before starting stimulants, with follow-up at 1 month and every 6 months thereafter. A published AHA scientific statement notes that stimulant medications produce mean increases of 2 to 4 mmHg in systolic blood pressure and 3 to 6 bpm in heart rate at therapeutic doses. [21] Patients with pre-existing hypertension or tachycardia require more frequent monitoring, which adds office visit costs.

Kansas does not require a separate state-mandated ADHD monitoring protocol beyond federal DEA Schedule II prescribing rules, but the standard of care aligns with AAP 2019 ADHD Clinical Practice Guideline recommendations: reassess medication response and side effects at each visit, update the KSPMP check, and document ongoing clinical necessity. [22]

A typical Kansas primary care visit for stimulant medication management runs $75 to $180 cash-pay or $20 to $45 after insurance, depending on visit complexity. Patients using telehealth platforms for follow-up may pay $49 to $99 per visit depending on the platform. Annual monitoring costs therefore range from roughly $100 to $720 per year on top of pharmacy costs.

Why the Adderall Shortage Matters for Kansas Patients in 2026

The national Adderall shortage that began in 2022 has had downstream effects on availability and pricing in Kansas pharmacies through 2025 and into 2026.

The FDA added amphetamine mixed salts to its official drug shortage list in October 2022, citing manufacturing delays at Teva's primary production facility. [10] While production has partially recovered, pharmacists in Kansas have reported intermittent stock issues for specific strengths, particularly 20 mg and 30 mg capsules. Patients who encounter a shortage should ask their pharmacist to check wholesaler availability across the pharmacy's network, request the pharmacist contact neighboring pharmacies, or ask their prescriber to consider a different manufacturer's generic that may be in stock.

Shortage status affects compounding legality: when a drug appears on the FDA shortage list, 503A compounding pharmacies in Kansas may legally compound copies of the commercial product, providing an additional supply pathway. Patients and prescribers can verify current shortage status at the FDA drug shortage database. [10]

A 2023 JAMA study (N=6.8 million pharmacy claims) found that patients who experienced a stimulant medication gap of 30 days or more had a 23% higher rate of ADHD-related emergency department visits in the 90 days following the gap compared to patients with continuous supply. [23] Supply continuity is therefore a clinical priority, not merely a convenience.

How Adderall XR Compares to Alternatives on Cost in Kansas

When Adderall XR is unavailable or cost-prohibitive, prescribers in Kansas have several evidence-based alternatives.

Vyvanse (lisdexamfetamine) brand carries a list price of approximately $380 per month in Kansas. The generic version of lisdexamfetamine became available in 2023 and runs approximately $70 to $90 per month at Kansas pharmacies as of 2025, still more expensive than generic MAS XR. [24]

Concerta (methylphenidate extended-release) and its generics cost $25 to $55 per month at Kansas retail pharmacies for standard doses. The generic osmotic extended-release methylphenidate (OROS-MPH) from Actavis and other manufacturers is often the cheapest Schedule II stimulant available in Kansas on a per-dose basis. [25]

Strattera (atomoxetine), a non-stimulant NRI, is covered by some Kansas insurance plans that exclude stimulants, including certain KanCare managed care plans. Generic atomoxetine costs approximately $30 to $60 per month and does not require Schedule II prescribing protocols. However, response rates are lower than for stimulants: a 2009 Cochrane meta-analysis (18 RCTs, N=2,762) found stimulants produced effect sizes of 0.8 to 1.0 on ADHD rating scales versus 0.6 to 0.7 for atomoxetine. [26]

Guanfacine ER (Intuniv) generic is available at $15 to $25 per month in Kansas and is covered by most KanCare formularies for pediatric ADHD. It is not a controlled substance, which simplifies prescribing and eliminates KSPMP requirements. For patients in whom stimulants are contraindicated or not covered, guanfacine ER represents the most affordable covered option in Kansas in 2026. [27]